Literature DB >> 2438955

Metastatic prostatic carcinoma to supradiaphragmatic lymph nodes. A clinicopathologic and immunohistochemical study.

K R Cho, J I Epstein.   

Abstract

We identified 26 cases of metastatic prostatic carcinoma in supradiaphragmatic lymph nodes from 1972-1987. All involved nodes (15 supraclavicular, eight cervical, two axillary, and one mediastinal) were taken from the left side. Of those cases with available data, serum acid phosphatase was normal in five of 21 (24%). Seven of 20 (35%) had no evidence of bone metastases. Rectal examination was normal in eight of 19 cases (42%). While seven cases had a history of prostate cancer, the rest presented with enlarged nodes alone or with simultaneous urinary obstructive symptoms. Eighteen patients died following node biopsy (mean 19.8 months, range 1-46 months). Twenty-two of 26 metastases were high grade and often were not histologically suggestive of prostate carcinoma. In general, immunohistochemical staining for prostate-specific acid phosphatase (PSAP) was more intense than for prostate-specific antigen (PSA), in contrast to several other reports using these antisera. Metastatic prostate carcinoma should be ruled out by using immunoperoxidase for PSA and PSAP in all men over 45 presenting with carcinoma of unknown primary origin in left-sided supradiaphragmatic lymph nodes, even in the absence of bony disease, elevated serum acid phosphatase (SAP), abnormal rectal examination, and a histologic picture suggesting prostate carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438955     DOI: 10.1097/00000478-198706000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

1.  Generalized lymphadenopathy: a rare presentation of disseminated prostate cancer.

Authors:  Basak Oyan; Huseyin Engin; Suayib Yalcin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Metastatic prostate carcinoma presenting as supraclavicular lymphadenopathy - is it unusual?

Authors:  S H Ahamed; A K Agarwal; P P J Raju
Journal:  Ann R Coll Surg Engl       Date:  2006-10       Impact factor: 1.891

3.  Prostate adenocarcinoma with negative immunohistochemical stain of prostate-specific antigen presenting with cervical mass: A case report.

Authors:  Liming Zhu; Cong Luo; Wei Wu; Jier Ying; Haijun Zhong
Journal:  J Res Med Sci       Date:  2013-09       Impact factor: 1.852

4.  Prostate adenocarcinoma presenting as a large supraclavicular mass.

Authors:  K Woo; R Wieczorek; P Torre; H Lepor
Journal:  Rev Urol       Date:  2001

5.  Supraclavicular lymphadenopathy as the initial presentation of metastatic prostate cancer: A case report and review of literature.

Authors:  Garson Chan; Trustin Domes
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

6.  [Mental neuropathy and pathologic fracture of the mandible as initial symptoms of metastatic prostate carcinoma].

Authors:  J Polligkeit; C Westendorff; S M Kröber; M Zerfowski; J Hoffmann
Journal:  Mund Kiefer Gesichtschir       Date:  2006-03

7.  Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer.

Authors:  Meftun Çulpan; Asıf Yıldırım; Turgay Turan; Turhan Çaşkurlu
Journal:  Turk J Urol       Date:  2017-12-19

8.  Metastatic prostate adenocarcinoma presenting as supraclavicular lymphadenopathy: a report of two cases.

Authors:  Mürsel Davarci; Ahmet Gokce; E Oguz Guven; Fatih R Yalcinkaya; Hasan Esen; Alper Sevinc
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

9.  Prostate cancer presenting as cervical lymphadenopathy.

Authors:  Siddharth P Dubhashi; Harsh Kumar; Sandeep R Nath
Journal:  Am J Case Rep       Date:  2012-08-28

10.  Expression of androgen receptor and prostate-specific antigen in male breast carcinoma.

Authors:  Noman Kidwai; Yun Gong; Xiaoping Sun; Charuhas G Deshpande; Anjana V Yeldandi; M Sambasiva Rao; Sunil Badve
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.